Project: A phase I clinical trial of intranasally administered influenza vaccine with or without an adjuvans.
10-AUG-00 – 31-DEC-05
Various intranasal influenza vaccines are administered to healthy adults (age:18-40). A control group is vaccinated with the intramuscular formulation. The trial lasts for 42 days consisting of 4 outpatient appointments followed by a phone call at day 180. The aim is to evaluate the safety, the immunogenicity (local + systemic) and the reactivity of the intranasal influenza vaccine.